Integrative analysis with microbial modelling and machine learning uncovers potential alleviators for ulcerative...

Area of Science:

• Microbiome research
• Computational biology
• Inflammatory bowel disease

Background:

• Ulcerative colitis (UC) is an inflammatory bowel disease with complex etiology linked to gut microbiome dysbiosis.
• Current therapeutic strategies for UC have limitations, necessitating the exploration of novel treatment avenues.
• Understanding strain-level microbial and metabolic alterations in UC is crucial for identifying therapeutic targets.

Purpose of the Study:

• To identify specific microbial strains and metabolites that can alleviate symptoms of ulcerative colitis.
• To leverage integrative analysis of metagenomics data and machine learning for novel UC therapeutic discovery.
• To validate potential therapeutic candidates in a preclinical model of colitis.

Main Methods:

• Individualized microbiome community modeling was performed using metagenomics data from the Integrated Human Microbiome Project.
• Advanced machine learning, specifically tree-based models, was employed to identify key microbial strains and metabolites.
• A dextran sulfate sodium (DSS)-induced mouse model of UC was used for experimental validation of identified alleviators.

Main Results:

• UC subjects exhibited significantly reduced α and β-diversity at the strain-level microbial population compared to controls.
• Distinct differences in predicted fecal metabolite profiles and strain-to-metabolite contributions were observed between UC patients and controls.
• Parabacteroides merdae ATCC 43,184 and N-acetyl-D-mannosamine were identified as potential alleviators and showed therapeutic effects in the UC mouse model.

Conclusions:

• An integrative approach combining microbiome modeling and machine learning can effectively identify potential alleviators for UC.
• Specific microbial strains, such as Parabacteroides merdae, and metabolites, like N-acetyl-D-mannosamine, show promise for UC treatment.
• This study highlights novel therapeutic targets and interventions for ulcerative colitis, warranting further clinical investigation.